BEVERLY, Mass. and TORONTO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX: HTL), a leading provider of precision instruments, laboratory equipment, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today announced that it will release its financial results for the three and six months ended June 30, 2024 before market open on Wednesday, August 14, 2024. The press release, with accompanying financial information, will be posted on the Company’s website at www.hamiltonthorne.ltd and on www.sedarplus.ca.
The Company’s updated investor presentation will be available on Hamilton Thorne’s website shortly after the release. The Company announced it will not be hosting a conference call.
About Hamilton Thorne Ltd. (www.hamiltonthorne.ltd)
Hamilton Thorne is a leading global provider of precision instruments, laboratory equipment, consumables, software, and services that reduce cost, increase productivity, improve results, and enable breakthroughs in Assisted Reproductive Technologies (ART), research, and cell biology markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed, Planer, Tek-Event, IVFtech, Microptic, Gynetics, and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne Ltd.’s customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.
Neither the TSX, nor its regulation services provider (as that term is defined in the policies of the TSX), accepts responsibility for the adequacy or accuracy of this release.
For more information, please contact: | ||||
Kate Torchilin, Pres. & CEO Hamilton Thorne Ltd. 978-921-2050 This email address is being protected from spambots. You need JavaScript enabled to view it. | Francesco Fragasso, CFO Hamilton Thorne Ltd. 978-921-2050 This email address is being protected from spambots. You need JavaScript enabled to view it. | Glen Akselrod Bristol Investor Relations 905-326-1888 This email address is being protected from spambots. You need JavaScript enabled to view it. |
Last Trade: | C$2.25 |
Daily Volume: | 15,308 |
Market Cap: | C$346.280M |
November 14, 2024 August 14, 2024 July 22, 2024 May 14, 2024 April 10, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB